{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yunusa I"],"funding":["NIA NIH HHS","AHRQ HHS","NIAMS NIH HHS"],"pagination":["e220194"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8874341"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["5(2)"],"pubmed_abstract":["<h4>Importance</h4>Some selective serotonin reuptake inhibitors (SSRIs) inhibit the enzymes responsible for the metabolism of oxycodone, a potent prescription opioid. The clinical consequences of this interaction on the risk of opioid overdose have not been elucidated.<h4>Objective</h4>To compare opioid overdose rates in patients initiating oxycodone while taking SSRIs that are potent inhibitors of the cytochrome-P450 2D6 enzyme (CYP2D6) vs SSRIs that are not.<h4>Design, setting, and participants</h4>This cohort study included adults who initiated oxycodone while receiving SSRI therapy between 2000 and 2020 whose data were included in 3 US health insurance databases.<h4>Exposures</h4>Use of SSRIs that strongly inhibit CYP2D6 enzyme (fluoxetine or paroxetine) vs use of other SSRIs at the ti"],"journal":["JAMA network open"],"pubmed_title":["Risk of Opioid Overdose Associated With Concomitant Use of Oxycodone and Selective Serotonin Reuptake Inhibitors."],"pmcid":["PMC8874341"],"funding_grant_id":["K23 AR076453","K01 AG068365","R01 HS027623"],"pubmed_authors":["Gagne JJ","Yunusa I","Bykov K","Yoshida K"],"additional_accession":[]},"is_claimable":false,"name":"Risk of Opioid Overdose Associated With Concomitant Use of Oxycodone and Selective Serotonin Reuptake Inhibitors.","description":"<h4>Importance</h4>Some selective serotonin reuptake inhibitors (SSRIs) inhibit the enzymes responsible for the metabolism of oxycodone, a potent prescription opioid. The clinical consequences of this interaction on the risk of opioid overdose have not been elucidated.<h4>Objective</h4>To compare opioid overdose rates in patients initiating oxycodone while taking SSRIs that are potent inhibitors of the cytochrome-P450 2D6 enzyme (CYP2D6) vs SSRIs that are not.<h4>Design, setting, and participants</h4>This cohort study included adults who initiated oxycodone while receiving SSRI therapy between 2000 and 2020 whose data were included in 3 US health insurance databases.<h4>Exposures</h4>Use of SSRIs that strongly inhibit CYP2D6 enzyme (fluoxetine or paroxetine) vs use of other SSRIs at the ti","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Feb","modification":"2025-04-04T12:44:09.936Z","creation":"2025-04-04T12:44:09.936Z"},"accession":"S-EPMC8874341","cross_references":{"pubmed":["35201310"],"doi":["10.1001/jamanetworkopen.2022.0194"]}}